Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471117 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
A Phase 4 study of Chronic Kidney Diseases, sponsored by The University of Texas at Arlington.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT03471117 is a Phase 4 study of Chronic Kidney Diseases that is actively recruiting participants, run by The University of Texas at Arlington. The registered enrollment target is 28 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03471117, a Phase 4 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by The University of Texas at Arlington.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pioglitazone
Study Locations (2)
Texas
- University of Texas at Arlington - Arlington
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471117
The ClinicalTrials.gov registry entry for NCT03471117 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (94% lower). The listed sponsor is The University of Texas at Arlington, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03471117 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03471117 about?
NCT03471117 is a clinical study titled "Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients". Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typ...
What is the current status of trial NCT03471117?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2018-04-01. Estimated completion is 2026-04-01.
What conditions does trial NCT03471117 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases.
What interventions are being tested in trial NCT03471117?
The interventions under investigation include: Placebo (OTHER), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT03471117?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03471117 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Iron in Children With Chronic Kidney Disease
RECRUITING · Phase 4
-
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
RECRUITING · Phase 4
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
Immunogenicity of HPV Vaccine in Transplant Recipients.
ACTIVE NOT RECRUITING · Phase 4
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.